Resultados de procura - Jean‐Pierre Bronowicki

Limitar resultados
  1. 1
    The Challenge of Prognosis and Staging for Hepatocellular Carcinoma

    The Challenge of Prognosis and Staging for Hepatocellular Carcinoma por Jorge A. Marrero, Masatoshi Kudo, Jean-Pierre Bronowicki

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort

    Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort por Xavier Adhoute, Guillaume Pénaranda, Jean‐Pierre Bronowicki, Jean‐Luc Raoul

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  3. 3
    Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases

    Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases por Julien Loubinoux, Jean‐Pierre Bronowicki, Inês A. C. Pereira, Jean-Louis Mougenel, Alain Le Faou

    Publicado 2002
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

    Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study por Shannon Ferrante, Jagpreet Chhatwal, Clifford A. Brass, Antoine C. El Khoury, Fred Poordad, Jean-Pierre Bronowicki, Elamin H. Elbasha

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Guided-VCTE: An Enhanced FibroScan Examination With Improved Guidance and Applicability

    Guided-VCTE: An Enhanced FibroScan Examination With Improved Guidance and Applicability por Cécile Bastard, Stéphane Audière, Julie Foucquier, Hugo Lorée, Véronique Miette, Jean‐Pierre Bronowicki, Christiane Stern, Cyrielle Caussy, Laurent Sandrin

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

    Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin por M. Diago, Mitchell L. Shiffman, Jean‐Pierre Bronowicki, Stefan Zeuzem, M. Rodríguez‐Torres, S. Chris Pappas, Andreas Tietz, David R. Nelson

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges

    The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges por Marie Müller, Vincent Haghnejad, Marion Schaefer, Guillaume Gauchotte, Bénédicte Caron, Laurent Peyrin‐Biroulet, Jean-Pierre Bronowicki, Cindy Neuzillet, Anthony Lopez

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  8. 8
    Rate of natural disease progression in patients with chronic hepatitis C

    Rate of natural disease progression in patients with chronic hepatitis C por Jean-Pierre Zarski, J. Mc Hutchison, Jean-Pierre Bronowicki, Nathalie Stürm, Richard Garcia‐Kennedy, Enkelejda Hodaj, Brenda Truta, Teresa L. Wright, Robert G. Gish

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year Study of 127 French Patients

    Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year Study of 127 French Patients por Jean‐Pierre Bronowicki, Denis Vetter, F Dumas, Karim Boudjéma, Robert Bader, Anne-Marie Weiss, Jean-Jacques Wenger, P Boissel, Marc‐André Bigard, Michel Doffoël

    Publicado 1994
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections

    Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections por Graham R. Foster, Christophe Hézode, Jean‐Pierre Bronowicki, Giampiero Carosi, Ola Weiland, Lieselotte Verlinden, Rolf van Heeswijk, Ben Van Baelen, Gastón Picchio, Maria Beumont

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France

    Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France por Jean‐Baptiste Chevaux, Abdelbasset Nani, Abderrahim Oussalah, Véronique Venard, Mouni Bensenane, Arthur Belle, Jean‐Louis Guéant, Marc‐André Bigard, Jean-Pierre Bronowicki, Laurent Peyrin–Biroulet

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection

    Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection por Olivier Hermine, François Lefrère, Jean‐Pierre Bronowicki, Xavier Mariette, Katayoun Jondeau, Virginie Eclache-Saudreau, B Delmas, Françoise Valensi, P. Cacoub, Christian Bréchot, Bruno Varet, Xavier Troussard

    Publicado 2002
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy

    Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy por Jean‐Pierre Bronowicki, Véronique Venard, C. Botté, Nathalie Monhoven, Isabelle Gastin, Laurence Choné, Hervé Hudziak, Bertrand Rhin, Christophe Delanoë, Alain Lefaou, Marc‐André Bigard, P Gaucher

    Publicado 1997
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Primary Lymphoma of the Liver: Clinical–Pathological Features and Relationship With Hcv Infection in French Patients

    Primary Lymphoma of the Liver: Clinical–Pathological Features and Relationship With Hcv Infection in French Patients por Jean‐Pierre Bronowicki, Catherine Bineau, Pierre Feugier, Olivier Hermine, Nicole Brousse, Frédéric Oberti, Marie-Christine Rousselet, Sébastien Dharancy, Philippe Gaulard, Jean–François Fléjou, Dominique Cazals–Hatem, Eric Labouyrie

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial

    869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results Fr... por Eric Lawitz, Xavier Forns, Stefan Zeuzem, Edward Gane, Jean‐Pierre Bronowicki, Pietro Andreoné, Andrzej Horban, Ashley Brown, Monika Peeters, Oliver Lenz, Sivi Ouwerkerk‐Mahadevan, Ronald Kalmeijer, Maria Beumont‐Mauviel

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

    Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+) por Vincent Leroy, Peter Angus, Jean‐Pierre Bronowicki, Gregory J. Dore, Christophe Hézode, Stephen Pianko, Stanislas Pol, Katherine Stuart, Edmund Tse, Fiona McPhee, Rafia Bhore, M.J. Jimenez-Exposito, Alexander Thompson

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

    Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3... por Jason Grebely, Stefan Mauss, Ashley Brown, Jean‐Pierre Bronowicki, Massimo Puoti, David Wyles, Macky Natha, Yanni Zhu, Junming Yang, Bruce Kreter, Diana M. Brainard, Chohee Yun, Val Carr, Gregory J. Dore

    Publicado 2016
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy

    Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy por Stella Maris Martínez, Juliette Foucher, Jean-Marc Combis, Sophie Métivier, Maurizia Rossana Brunetto, Dominique Capron, Marc Bourlière, Jean‐Pierre Bronowicki, Thông Dao, M. Maynard-Muet, Damien Lucidarme, Wassil Merrouche, Xavier Forns, Victor de Lédinghen

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B

    A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B por Patrick Marcellin, Herve Momméja-Marin, Stephen L. Sacks, George Lau, D. Séréni, Jean‐Pierre Bronowicki, Brian Conway, Christian Trépo, Robert M. Blum, Byung Chul Yoo, Elsa Mondou, J. Sorbel, A. Lynn Snow, Franck Rousseau, Hyo‐Suk Lee

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

    Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial por Mark S. Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, Tarik Asselah, Jean‐Michel Pawlotsky, Stephen D. Shafran, Stanislas Pol, Stefan Mauss, Dominique Larrey, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Schérer, Gerhard Nehmiz, Gerhard Steinmann, Wulf O. Böcher

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: